TY - JOUR AU - Altura, B. T. AU - Altura, B. M. PY - 1980 DA - 1980// TI - Withdrawal of magnesium causes vasospasm while elevated magnesium produces relaxation of tone in cerebral arteries JO - Neurosci Lett VL - 20 UR - https://doi.org/10.1016/0304-3940(80)90168-8 DO - 10.1016/0304-3940(80)90168-8 ID - Altura1980 ER - TY - STD TI - Assarzadegan, F., H. Tabesh, S.-M. Hosseini-Zijoud, A. D. Beale, A. Shoghli, M. G. Yazdi, B. Mansouri, O. Hesami, N. B. Moghadam and H. D. J. I. R. C. M. J. Kasmaei (2016). "Comparing zonisamide with sodium valproate in the management of migraine headaches: double-blind randomized clinical trial of efficacy and safety." 18(9) ID - ref2 ER - TY - STD TI - Bigal, M. E., A. M. Rapoport, R. B. Lipton, S. J. Tepper, F. D. J. H. T. J. o. H. Sheftell and F. Pain (2003). "Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine." 43(4): 336–342 ID - ref3 ER - TY - STD TI - Bostani, A., A. Rajabi, N. Moradian, N. Razazian and M. J. I. J. o. N. Rezaei (2013). "The effects of cinnarizine versus sodium valproate in migraine prophylaxis." 123(7): 487–493 ID - ref4 ER - TY - STD TI - Canger, R. and L. J. C. D. I. Guidolin (2000). "Clinical Efficacy and Tolerability of Magnesium Valproate as Monotherapy in Patients with Generalised or Partial Epilepsy." 20(4): 215–221 ID - ref5 ER - TY - STD TI - Cutrer, F., V. Limmroth and M. J. C. Moskowitz (1997). "Possible mechanisms of valproate in migraine prophylaxis." 17(2): 93–100 ID - ref6 ER - TY - STD TI - Dalla Volta, G. J. I. J. N. B. D. (2017). "Combi-nation of Tanacethum Partenium, 5-Hy-drossitriptophan (5-Http) and Magnesium in the Prophylaxis of Episodic Migraine without Aura (AURASTOP®)-An Obser-vational Study.(2017) Int J Neuro Brain Dis 4 (3): 1–4." 4(3) ID - ref7 ER - TY - STD TI - Daniel, O. and A. J. C. t. o. i. n. Mauskop (2016). "Nutraceuticals in acute and prophylactic treatment of migraine." 18(4): 14 ID - ref8 ER - TY - STD TI - Dolati, S., R. Rikhtegar, A. Mehdizadeh and M. J. B. t. e. r. Yousefi (2019). "The Role of Magnesium in Pathophysiology and Migraine Treatment." 1–9 ID - ref9 ER - TY - STD TI - Facchinetti, F., G. Sances, P. Borella, A. R. Genazzani, G. J. H. T. J. o. H. Nappi and F. Pain (1991). "Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium." 31(5): 298–301 ID - ref10 ER - TY - STD TI - Farhadi, Z., S. Alidoost, M. Behzadifar, R. Mohammadibakhsh, N. Khodadadi, R. Sepehrian, R. Sohrabi, M. T. Mirghaed, M. Salemi and H. J. I. R. C. M. J. Ravaghi (2016). "The prevalence of migraine in Iran: A systematic review and meta-analysis." 18(10) ID - ref11 ER - TY - STD TI - Faryadi, Q. J. I. J. o. A. (2012). "The magnificent effect of magnesium to human health: a critical review." 2(3) ID - ref12 ER - TY - STD TI - Fueta, Y., A. Siniscalchi, V. Tancredi and M. J. E. Avoli (1995). "Extracellular magnesium and anticonvulsant effects of valproate in young rat hippocampus." 36(4): 404–409 ID - ref13 ER - TY - STD TI - Giorgio Dalla, V., P. Zavarize, G. Ngonga, A. Pezzini, G. J. I. J. o. N. Dalla Volta and B. Disorders (2017). "Combination of Tanacethum Partenium, 5-Hydrossitriptophan (5-Http) and Magnesium in the Prophylaxis of Episodic Migraine without Aura (AURASTOP®) An Observational Study." 4(1): 0–0 ID - ref14 ER - TY - STD TI - Ha, H. and A. J. A. f. p. Gonzalez (2019). "Migraine Headache Prophylaxis." 99(1) ID - ref15 ER - TY - STD TI - Hesami, O., M. R. Shams, L. Ayazkhoo, F. Assarzadegan, B. S. Lima, H. D. Kasmaei and M. J. I. j. o. p. r. I. Sistanizad (2018). "Comparison of pregabalin and sodium valproate in migraine prophylaxis: a randomized double-blinded study." 17(2): 783 ID - ref16 ER - TY - JOUR AU - Hoffmann, J. AU - Charles, A. PY - 2018 DA - 2018// TI - Glutamate and its receptors as therapeutic targets for migraine JO - Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics VL - 15 UR - https://doi.org/10.1007/s13311-018-0616-5 DO - 10.1007/s13311-018-0616-5 ID - Hoffmann2018 ER - TY - STD TI - Holla, R., B. Darshan, Y. Z. Ying, T. Raymond, E. Ponniah, K. S. San, N. Y. J. I. J. o. P. H. R. Yen and Development (2019). "Clinical Characteristics and Associated Disability of Headache among Medical Undergraduates." 10(8): 647–650 ID - ref18 ER - TY - STD TI - Homam, M., A. Farajpour, S. Khadem and Z. J. C. J. o. N. S. Mostafavian (2016). "The experiential comparison of levetiracetam efficacy in migraine headache with sodium valproate." 2(2): 42–49 ID - ref19 ER - TY - STD TI - Ichikawa, M., H. Katoh, T. Kurihara and M. J. J. o. C. N. Ishii (2016). "Clinical response to valproate in patients with migraine." 12(4): 468–475 ID - ref20 ER - TY - STD TI - Karimi, N., A. Razian and M. J. A. N. B. Heidari (2019). "The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study." 1–7 ID - ref21 ER - TY - STD TI - Keyvan, G. and M.-B. J. P. j. o. b. s. P. Abolfazl (2009). "Comparison of treatment effect of sodium valproate, propranolol and tricyclic antidepressants in migraine." 12(15): 1098–1101 ID - ref22 ER - TY - STD TI - Köseoglu, E., A. Talaslıoglu, A. S. Gönül and M. J. M. r. Kula (2008). "The effects of magnesium prophylaxis in migraine without aura." 21(2): 101–108 ID - ref23 ER - TY - STD TI - Lingam, I. and N. J. J. D. n. Robertson (2018). "Magnesium as a neuroprotective agent: a review of its use in the fetus, term infant with neonatal encephalopathy, and the adult stroke patient." 40(1): 1–12 ID - ref24 ER - TY - STD TI - Maier, J. A., G. Pickering, E. Giacomoni, A. Cazzaniga and P. J. N. Pellegrino (2020). "Headaches and Magnesium: Mechanisms, Bioavailability, Therapeutic Efficacy and Potential Advantage of Magnesium Pidolate." 12(9): 2660 ID - ref25 ER - TY - STD TI - Mathew, N. T., J. R. Saper, S. D. Silberstein, L. Rankin, H. G. Markley, S. Solomon, A. M. Rapoport, C. J. Silber and R. L. J. A. o. N. Deaton (1995). "Migraine prophylaxis with divalproex." 52(3): 281–286 ID - ref26 ER - TY - STD TI - Parikh, S. K. and S. D. J. C. t. o. i. n. Silberstein (2019). "Current Status of Antiepileptic Drugs as Preventive Migraine Therapy." 21(4): 16 ID - ref27 ER - TY - STD TI - Pringsheim, T., W. Davenport, G. Mackie, I. Worthington, M. Aubé, S. N. Christie, J. Gladstone and W. J. J. C. J. N. S. Becker (2012). "Canadian Headache Society guideline for migraine prophylaxis." 39(2 Suppl 2): S1–59 ID - ref28 ER - TY - JOUR AU - Romoli, M. AU - Costa, C. AU - Siliquini, S. AU - Corbelli, I. AU - Eusebi, P. AU - Bedetti, C. AU - Caproni, S. AU - Cupini, L. M. AU - Calabresi, P. AU - Sarchielli, P. J. C. PY - 2018 DA - 2018// TI - Antiepileptic drugs in migraine and epilepsy JO - Who is at increased risk of adverse events? VL - 38 ID - Romoli2018 ER - TY - STD TI - Rondon, L., A. Privat, L. Daulhac, N. Davin, A. Mazur, J. Fialip, A. Eschalier and C. J. T. J. o. p. Courteix (2010). "Magnesium attenuates chronic hypersensitivity and spinal cord NMDA receptor phosphorylation in a rat model of diabetic neuropathic pain." 588(21): 4205–4215 ID - ref30 ER - TY - STD TI - Safar, M. M., D. M. Abdallah, N. M. Arafa and M. T. J. B. r. Abdel-Aziz (2010). "Magnesium supplementation enhances the anticonvulsant potential of valproate in pentylenetetrazol-treated rats." 1334: 58–64 ID - ref31 ER - TY - STD TI - Shahien, R. and K. J. J. o. c. n. s. d. Beiruti (2012). "Preventive agents for migraine: focus on the antiepileptic drugs." 4: JCNSD. S9049 ID - ref32 ER - TY - STD TI - Shaygannejad, V., M. Janghorbani, A. Ghorbani, F. Ashtary, N. Zakizade, V. J. H. T. J. o. H. Nasr and F. Pain (2006). "Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study." 46(4): 642–648 ID - ref33 ER - TY - STD TI - Shin, H. E., J. W. Park, Y. I. Kim and K. S. J. J. o. c. n. Lee (2008). "Headache Impact Test-6 (HIT-6) scores for migraine patients: Their relation to disability as measured from a headache diary." 4(4): 158–163 ID - ref34 ER - TY - STD TI - Skljarevski, V., M. Matharu, B. A. Millen, M. H. Ossipov, B.-K. Kim and J. Y. J. C. Yang (2018). "Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial." 38(8): 1442–1454 ID - ref35 ER - TY - STD TI - Slavin, M., H. Li, M. Khatri, C. J. H. T. J. o. H. Frankenfeld and F. Pain (2021). "Dietary magnesium and migraine in adults: A cross-sectional analysis of the National Health and Nutrition Examination Survey 2001–2004." ID - ref36 ER - TY - STD TI - Spasić, M., M. Živković and S. J. M. B. Lukić (2003). "Prophylactic treatment of migraine by valproate." 10(3): 106–110 ID - ref37 ER - TY - STD TI - Sprenger, T., M. Viana and C. J. N. Tassorelli (2018). "Current prophylactic medications for migraine and their potential mechanisms of action." 15(2): 313–323 ID - ref38 ER - TY - STD TI - Steiner TJ, Birbeck GL, Jensen R, Katsarava Z, Martelletti P, Stovner LJ (2011) The global campaign, world health organization and lifting the burden: collaboration in action. BioMed Central ID - ref39 ER - TY - STD TI - Taubert, K. J. F. d. M. (1994). "Magnesium in migraine. Results of a multicenter pilot study." 112(24): 328–330 ID - ref40 ER - TY - STD TI - Von Luckner, A., F. J. H. T. J. o. H. Riederer and F. Pain (2018). "Magnesium in migraine prophylaxis—is there an evidence-based rationale? A systematic review." 58(2): 199–209 ID - ref41 ER - TY - STD TI - Vuckovic, S., D. Srebro, K. Savic Vujovic and M. J. P. b. Prostran (2015). "The antinociceptive effects of magnesium sulfate and MK-801 in visceral inflammatory pain model: the role of NO/cGMP/K+ ATP pathway." 53(11): 1621-1627 ID - ref42 ER - TY - STD TI - Waldrop, M. A. and S. J. J. C. t. o. i. n. Kolb (2019). "Current Treatment Options in Neurology—SMA Therapeutics." 21(6): 25 ID - ref43 ER - TY - STD TI - Weatherall, M. W. J. T. a. i. c. d. (2015). "The diagnosis and treatment of chronic migraine." 6(3): 115–123 ID - ref44 ER - TY - STD TI - Weglicki, W. B., T. M. J. A. J. o. P.-R. Phillips, Integrative and C. Physiology (1992). "Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis." 263(3): R734-R737 ID - ref45 ER -